Pomerantz Law Firm Announces the Filing of a Class Action Against EyePoint, Inc. and Certain Officers - EYPT
NEW YORK, NY / ACCESS Newswire / November 17, 2026 /Pomerantz LLP announces that a class action lawsuit has been filed against EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 26-cv-07418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired EyePoint securities between May 27, 2025 and August 14, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants ' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are an investor who purchased or otherwise acquired EyePoint securities during the Class Period, you have until January 19, 2027, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
EyePoint develops and commercializes therapeutics to purportedly improve the lives of patients with serious retinal diseases. The Company 's pipeline leverages its proprietary bioerodible "Durasert E" technology for sustained intraocular drug delivery.
EyePoint 's lead product candidate is DURAVYU. During the Class Period, Defendants were evaluating DURAVYU for the treatment of, inter alia, wet age-related macular degeneration ("wet AMD") in EyePoint 's Phase 3 LUGANO and LUCIA trials. The primary endpoint of both trials was the average change in best corrected visual acuity ("BCVA") at weeks 52 and 56 versus baseline.
At all relevant times while the LUGANO and LUCIA trials were ongoing, Defendants touted DURAVYU 's purportedly "differentiated profile," as well as its "uniquely suited" mechanism of action and "robust" and "best-in-class" efficacy profile, purportedly demonstrated by data from other studies. Critically, Defendants cited to these other studies to suggest that the results of the LUGANO and LUCIA trials were likely to be favorable, while consistently touting DURAVYU 's clinical, regulatory, and commercial prospects for the treatment of wet AMD.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company 's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU 's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants ' public statements were materially false and misleading at all relevant times.
The truth began to emerge on August 17, 2026, when EyePoint issued a press release announcing topline results from the LUGANO trial. The press release disclosed, in relevant part, that "the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset, confounded by [an] asymmetric cohort."
On this news, EyePoint 's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.
Although Defendants asserted that the LUGANO trial 's failure was the result an "asymmetric cohort" and "due to chance alone", such that investors could expect more positive results in the LUCIA trial, the LUCIA trial ultimately likewise failed to meet its prespecified primary efficacy endpoint, negating this assertion.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:Pomerantz LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.











